Gabapentin Capsule
Product Images NDC 63187-392

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 63187-392). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 01)

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 01)
This is a dosage table for Gabapentin based on the patient's renal function. The table provides the dosage range and regimen for patients with different creatinine clearance levels. There is also a supplemental post-hemodialysis dose for patients on hemodialysis. The table includes the dosage frequency acronyms TID, BID, and QD. For patients with creatinine clearance below 15 mL/min, the daily dose should be reduced proportionally. Patients on hemodialysis should receive maintenance doses based on creatinine clearance estimates and a supplemental post-hemodialysis dose after each 4 hours of hemodialysis.*
FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 02)

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 03)

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 03)
This text presents a table of risks associated with antiepileptic drugs based on different indications. It also compares the incidence of events in patients taking the drugs versus those taking a placebo.*
FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 04)

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 04)
This is a table showing the adverse reactions in pooled placebo-controlled trials in postherpetic neuralgia for Gabapentin and Placebo. The table shows the percentage of patients who experienced specific adverse reactions in various body systems such as the Body as a whole, Digestive system, Metabolic and Nutritional Disorders, Nervous System, Respiratory System, and Special Senses. The adverse reactions for Gabapentin and Placebo are compared and presented in the table.*
FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 05)

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 05)
This is a table of adverse reactions observed in two groups of patients with epilepsy, one group receiving Gabapentin and the other group receiving a placebo. The table compares the percentage of patients in each group who experienced different adverse reactions. The adverse reactions are divided into different categories such as body as a whole, cardiovascular, digestive system, nervous system, respiratory system, skin and appendages, urogenital system, and special senses. The table also mentions that the patients in both groups were receiving background anti-epileptic drug therapy. Amblyopia, one of the adverse reactions, is described as blurred vision.*
FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 06)

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 06)
This is a table showing the adverse reactions observed in pediatric epilepsy patients between the ages of 3 to 12 years who were given either Gabapentin or a placebo as an add-on treatment. The table lists the different adverse reactions and the percentage of patients who experienced them. The adverse reactions include body rash, viral infection, fever, increased weight, fatigue, nausea, vomiting, somnolence, hostility, emotional lability, dizziness, hyperkinesia, bronchitis and respiratory infection. The number of patients in each group and the fact that all patients were on background antiepileptic drug therapy is also mentioned.*
FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 07)

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 08)

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 08)
This is a table showing the dosages, duration and number of patients for two controlled studies on Gabapentin for PHN treatment. Study 1 lasted 8 weeks and the patients received a daily dosage of 3600 mg divided into 3 doses. The study included 113 patients who received Gabapentin and 116 who received a placebo. Study 2 lasted 7 weeks and patients received a daily Gabapentin dosage of either 1800 or 2400 mg divided into 3 dose intakes. The study included 223 patients receiving Gabapentin and 11 receiving a placebo. The total number of patients included in both studies was 227.*
FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 09)

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 10)

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 11)

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 11)
The text is a figure caption reporting the proportion of patients with >50% reduction in pain score at endpoint for controlled postherpetic neuralgia (PHN) studies. It also mentions the statistical significance (p<0.001) for one of the studies. The values and dosage of the treatments used in the studies are mentioned as well. Therefore, this text describes the results of some clinical trials using different medications to manage PHN.*
FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 12)

FDA Label Image

63187-392-90 (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 13)

63187-392-90 (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 13)
This is a medication description for gabapentin 100mg capsules. The medication comes in a bottle of 90 capsules. Each capsule contains 100mg of gabapentin. The capsules are white opaque with an imprint of "100mg" and "1G321". The medication guide should be dispensed with the medication. The medication is manufactured by Ascent Pharmaceuticals, Inc. The lot number is 00000, and the expiration is 00/00/00. The medication should be stored between 20°-25°C (68°-77°F). The medication is packaged by Proficient Rx LP in Thousand Oaks, CA.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.